Regulatory · source year

2025 regulatory records

71 selected, source-linked regulatory records dated 2025. This is selective source coverage, not a complete timeline.

Dated records

71 selected records.

Peptide profiles

30 connected profiles.

Cited sources

71 distinct public records.

Cited chronology

Dated source records

All record types in 2025 →

December 2025

12 records

Elamipretide

Federal Register notice 2025-23409

The Federal Register published notice 2025-23409, attributed to FDA and its parent HHS department, on 2025-12-19. Its official title is “Issuance of Priority Review Voucher; Rare Pediatric Disease Product; FORZINITY (Elamipretide),” and PeptideScanner's exact reviewed identity mapping connects the document to Elamipretide.

Source: Federal Register via GovInfo ↗

→

Glucagon + 5 more

Federal Register notice 2025-22131

The Federal Register published notice 2025-22131, attributed to FDA and its parent HHS department, on 2025-12-05. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Glucagon, Liraglutide, Semaglutide, Teriparatide, Tirzepatide and Vosoritide.

Source: Federal Register via GovInfo ↗

→

November 2025

10 records

Glucagon + 1 more

Federal Register notice 2025-20548

The Federal Register published notice 2025-20548, attributed to FDA and its parent HHS department, on 2025-11-21. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Glucagon and Tirzepatide.

Source: Federal Register via GovInfo ↗

→

October 2025

3 records

Exenatide + 1 more

Federal Register notice 2025-19281

The Federal Register published notice 2025-19281, attributed to FDA and its parent HHS department, on 2025-10-02. Its official title is “Pediatric Advisory Committee (PAC); Notice of Meeting; Establishment of a Public Docket; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Exenatide and Linaclotide.

Source: Federal Register via GovInfo ↗

→

Semaglutide

Federal Register notice 2025-19345

The Federal Register published notice 2025-19345, attributed to FDA and its parent HHS department, on 2025-10-02. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Semaglutide.

Source: Federal Register via GovInfo ↗

→

September 2025

4 records

Bivalirudin

Federal Register notice 2025-18453

The Federal Register published notice 2025-18453, attributed to FDA and its parent HHS department, on 2025-09-24. Its official title is “Elite Laboratories, Inc., et al.; Withdrawal of Approval of 72 Abbreviated New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Bivalirudin.

Source: Federal Register via GovInfo ↗

→

August 2025

8 records

Palopegteriparatide

Federal Register notice 2025-16269

The Federal Register published notice 2025-16269, attributed to FDA and its parent HHS department, on 2025-08-26. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; YORVIPATH,” and PeptideScanner's exact reviewed identity mapping connects the document to Palopegteriparatide.

Source: Federal Register via GovInfo ↗

→

Exenatide

Federal Register notice 2025-14683

The Federal Register published notice 2025-14683, attributed to FDA and its parent HHS department, on 2025-08-04. Its official title is “Teva Branded Pharmaceutical Products R&D, Inc., et al.; Withdrawal of Approval of 39 New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Exenatide.

Source: Federal Register via GovInfo ↗

→

July 2025

6 records

June 2025

8 records

Zilucoplan

Federal Register notice 2025-11314

The Federal Register published notice 2025-11314, attributed to FDA and its parent HHS department, on 2025-06-20. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; ZILBRYSQ,” and PeptideScanner's exact reviewed identity mapping connects the document to Zilucoplan.

Source: Federal Register via GovInfo ↗

→

May 2025

7 records

Zilucoplan

Federal Register notice 2025-09068

The Federal Register published notice 2025-09068, attributed to FDA and its parent HHS department, on 2025-05-21. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Zilucoplan.

Source: Federal Register via GovInfo ↗

→

April 2025

6 records

Daptomycin

Federal Register notice 2025-06048

The Federal Register published notice 2025-06048, attributed to FDA and its parent HHS department, on 2025-04-09. Its official title is “21st Century Cures Act: Annual Compilation of Notices of Updates From the Susceptibility Test Interpretive Criteria Web Page; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Daptomycin.

Source: Federal Register via GovInfo ↗

→

March 2025

1 record

February 2025

4 records

January 2025

2 records

Triptorelin

Federal Register rule 2025-01226

The Federal Register published rule 2025-01226, attributed to FDA and its parent HHS department, on 2025-01-21. Its official title is “New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Applications; Change of Sponsor; Change of Sponsor Address,” and PeptideScanner's exact reviewed identity mapping connects the document to Triptorelin.

Source: Federal Register via GovInfo ↗

→